{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:22:08Z","timestamp":1792671728179,"version":"4.5.0"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic value of the PSA ELIMination rate constant K (PRO\u2010KELIM) score was investigated in patients with metastatic castration\u2010sensitive prostate cancer (mCSPC) treated with novel androgen receptor inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study included 160 patients diagnosed with prostate adenocarcinoma between 2011 and 2024 who received enzalutamide or abiraterone during the mCSPC and had at least three PSA measurements within the first 100 days of treatment. The patients were categorized into favorable (PRO\u2010KELIM\u2009\u2265\u20091.0) and unfavorable (PRO\u2010KELIM\u2009&lt;\u20091.0) groups. Progression\u2010free survival (PFS) and overall survival (OS) were analyzed using the Kaplan\u2013Meier survival analysis and Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median PFS was significantly higher in the favorable group than in the unfavorable group (not reached vs. 40.0 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The estimated 2\u2010year PFS rates in the favorable and unfavorable groups were 78% and 52%, respectively. In multivariate analyses, a high PRO\u2010KELIM score (HR 2.99; 95% CI 1.35\u20136.66,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) and good initial response to treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) were independent favorable prognostic factors for PFS. The median OS did not differ significantly between the groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.27). PRO\u2010KELIM score was not an independent prognostic factor for OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.76).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that the PRO\u2010KELIM score can be a valuable prognostic tool in the mCSPC to assess early treatment response and predict disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70098","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:00:42Z","timestamp":1763967642000},"page":"393-400","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Effect of KELIM Score of Prostate\u2010Specific Antigen in Hormone\u2010Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways"],"prefix":"10.1002","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2875-6876","authenticated-orcid":false,"given":"Yusuf","family":"Ilhan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Antalya City Hospital Antalya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-9501","authenticated-orcid":false,"given":"Murat","family":"Araz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Necmettin Erbakan University Konya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-471X","authenticated-orcid":false,"given":"Ali Fuat","family":"Gurbuz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Necmettin Erbakan University Konya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-3842","authenticated-orcid":false,"given":"Semiha","family":"Urvay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kayseri Ac\u0131badem Hospital Kayseri Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-3398","authenticated-orcid":false,"given":"Muslih","family":"Urun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University Van Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-5500","authenticated-orcid":false,"given":"Berrak","family":"Mermit Ercek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University Van Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-728X","authenticated-orcid":false,"given":"Ozden","family":"Ozilice","sequence":"additional","affiliation":[{"name":"Alanya District Health Directorate, Alanya Antalya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-2075","authenticated-orcid":false,"given":"Onur Yazdan","family":"Balcik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Alaaddin Keykubat University Antalya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-7216","authenticated-orcid":false,"given":"Canan","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Afyonkarahisar Health Sciences University  Afyon Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1235-9363","authenticated-orcid":false,"given":"Hacer","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Afyonkarahisar Health Sciences University  Afyon Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0853-4096","authenticated-orcid":false,"given":"Ismail","family":"Beypinar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Alaaddin Keykubat University Antalya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt382"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010098"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0054"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00208"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030815"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.04.009"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30082-8"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1493"},{"issue":"24","key":"e_1_2_13_15_1","first-page":"00192","article-title":"Prostate\u2010Specific Antigen Nadir and Cancer\u2010Control Outcomes in Real\u2010World Apalutamide\u2010Treated Metastatic Hormone\u2010Sensitive Prostate Cancer Patients: A Single\u2010Center Analysis","volume":"2588","author":"Wenzel M.","year":"2024","journal-title":"European Urology Oncology"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1549"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2024.11.007"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:51:51Z","timestamp":1768035111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/pros.70098"],"URL":"https:\/\/doi.org\/10.1002\/pros.70098","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"2025-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}